Chronic liver disease develops when the liver is injured repeatedly over years until scar tissue begins to replace working liver cells. Mexico carries a notably high burden of liver disease, with alcohol-related liver disease and non-alcoholic fatty liver disease (NAFLD/NASH) — closely linked to the country’s high rates of obesity and type 2 diabetes — among the leading causes, alongside chronic hepatitis. Once fibrosis progresses to cirrhosis, the scarring itself is not reversible with any treatment currently available, and hepatology care concentrates on eliminating the cause, preventing complications such as fluid accumulation or variceal bleeding, and assessing candidacy for transplant when the disease decompensates. Stem Cell Cure India offers an evaluation for patients wanting to understand where regenerative options fit into that picture.
Liver transplant capacity in Mexico is limited relative to the number of patients who need one, and waiting lists can be long, particularly outside major transplant centres. Patients with compensated cirrhosis who are not yet transplant candidates, or who have addressed the underlying cause but are left with established scarring, often want to know whether anything can be done beyond monitoring. Coming to India gives access to FibroScan and other assessment tools alongside a candid discussion of whether stem cell therapy is a reasonable addition in their specific situation.
Dr. Tyagi leads regenerative medicine protocol design at Stem Cell Cure India, overseeing stem cell sourcing, lab processing, and treatment planning for patients being evaluated for chronic liver disease and other regenerative conditions.
Dr. Singh brings over three decades of clinical experience in general medicine and surgery, and assesses the general fitness of patients arriving from Mexico before any treatment plan is confirmed.
Mesenchymal Stem Cells (MSCs) are being examined for anti-inflammatory and possible antifibrotic activity, and for whether they might support liver function in some chronic liver disease research settings. What patients need to hear clearly is that established cirrhotic scarring is not known to be reversed by this or any other available treatment, and that stem cell therapy is in no sense an alternative to liver transplant assessment where the disease has decompensated. It is also not a treatment for the underlying cause: alcohol-related disease needs abstinence, NAFLD/NASH needs metabolic management, and viral hepatitis needs antiviral therapy. Any discussion here is an addition to that care, never a substitute for it.
The cause of the liver disease, how advanced the scarring is, and whether complications have occurred all determine the answer. Before travel from Mexico, our team reviews:
No. Scarring that has already formed in the liver is considered permanent with treatments available today, and stem cell therapy does not reverse it. It is discussed only as a possible support for liver function alongside hepatology care for the underlying cause.
No. Where cirrhosis has decompensated, transplant assessment by a hepatologist remains the standard of care and should continue. Stem cell therapy is not a substitute for it under any circumstances.
Managing the metabolic cause — blood sugar, weight, and lipids — remains central to care and matters for suitability. Whether anything further is reasonable depends on the degree of remaining scarring and liver function, which is what the reports are reviewed for.
Recent liver function tests, a Child-Pugh or MELD score if calculated, an ultrasound or FibroScan report, your hepatitis panel, and details of any complications you have had.
Most patients plan for 7 to 10 days, depending on which investigations are repeated here and what the plan requires.
It varies with the stage of disease and the plan proposed, so a quote is prepared individually once your reports have been reviewed.
Source: These are real, verified Google reviews currently published on stemcellcure.in — pulled from our Google Business Profile (5.0★, 33+ reviews).
